TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03545893
Drug: Ibuprofen 600 mg
Normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 600mg prescription, to be taken 1 tablet as needed every 6 hours for pain.
Study: NCT00176618
Drug: sulindac
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulindac 150 mg po BID
Study: NCT02910011
Drug: Nanodox 1% (doxycycline monohydrate hydrogel)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be asked to apply NanoDOX® Hydrogel 1% once daily at bedtime for up to four weeks or until complete clearance whichever is sooner
Study: NCT01577550
Drug: Placebo, i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single i.v. administration of placebo
Study: NCT01577550
Drug: Placebo, s.c.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single s.c. administration of placebo
Study: NCT00796107
Drug: RG1507
Approvals — FDA: no, EMA: no, PMDA: no
Description: R1507 was administered at a dose 16 mg/kg every 3 weeks.
Study: NCT01988246
Drug: Sham
Normalized name: SHAMPOO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection. No actual injection. No medication is used.
Study: NCT01572727
Drug: BKM120 matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib maching plaxcebo were supplied as 100 mg and 50 mg hard gelatin capsules.~Buparlisib placebo was dosed on a flat scale of mg/day and was not adjusted to body weight or body surface area.
Study: NCT01572727
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib (BKM120) were supplied as 100 mg and 50 mg hard gelatin capsules. Buparlisib was dosed on a flat scale of mg/day and was not adjusted to body weight or body surface area.
Study: NCT02166008
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03071692
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-877 matching placebo tablet
Study: NCT03173040
Drug: NiuBangZi pill or NiuBangZi pill placebo
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the treatment group (NiuBangZi pill group), patients will be instructed to dissolve NiuBangZi pill (4 g) in 200 mL hot water and take the solution orally twice a day for 3 months. While patients in the placebo group will take NiuBangZi pill placebo as the same way. Besides that, both groups will also administrate MTX (5 mg per week) in addition, and glucocorticoid (less than 5mg a day) if necessary, but any other drugs especially herbs not permit.
Study: NCT03651089
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection of sterile saline
Study: NCT00687648
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by mouth
Study: NCT04022876
Drug: ALRN-6924
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALRN-6924 administered IV on Days 0-2 prior to carboplatin and pemetrexed administered IV on Day 1 of every 21-day cycle.
Study: NCT04022876
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered IV on Days 0-2 prior to carboplatin and pemetrexed administered IV on Day 1 of every 21-day cycle.
Study: NCT04022876
Drug: ALRN-6924
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALRN-6924 administered IV on Days 0-4 prior to topotecan administered IV on Days 1-5 of every 21-day cycle.
Study: NCT00687648
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by mouth
Study: NCT00687648
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by mouth
Study: NCT05984953
Drug: statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of rosuvastatin daily for 8-12 weeks
Study: NCT02363946
Drug: ARC-AAT Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: RNA interference-based, liver-targeted therapeutic
Study: NCT04050826
Drug: Oraqix Parodontal-Gel (Dentsply Detrey GmbH, Germany)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application
Study: NCT03119467
Drug: RP4010
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses starting at 25 mg
Study: NCT01302119
Drug: AN2690 Topical Solution, 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: AN2690 Topical Solution, 5%, applied once daily for 48 weeks
Study: NCT01302119
Drug: Solution Vehicle
Normalized name: Flavor Sweet Oral Solution Vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks
Study: NCT02466022
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus 0.1cc/kg Normal Saline over 10 min
Study: NCT02466022
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal Fentanyl 10ug
Study: NCT04207931
Drug: Topical steroid class I-II
Normalized name: Defend II Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: applied once daily - 18 month duration of the study
Study: NCT03713632
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 300mg every 2 or every 4 weeks
Study: NCT04207931
Drug: Doxycyline
Normalized name: Doxycycline 50 MG Oral Tablet [DOXYCYLINE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral antibiotic twice daily for 6 months
Study: NCT03853512
Drug: BAY207543 (Bepanthol, Bepantol® Derma Spray)
Normalized name: Derma Gran Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Product is applied to one side of the inguinal region.
Study: NCT02888730
Drug: Tobramycin nebulized nasally
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Two sonic nebulizations per day will be realized by patients: morning and evening during 15 days. There should be a maximum of 12 hours between the 2 doses but shall not be less than 6 hours. The dosage should not be adjusted to body weight. All patients will receive one ampoule of tobramycin twice a dayAmpoules of tobramycin are filled by 5 ml containing 300 mg of tobramycin and 11.25 mg of sodium chloride. Bulb should be employed in nebulizer and administered by the inhalation route approximately 15 minutes to complete.Antibiotic retained for the study, tobramycin is manufactured by the Pharmacie à Usage Interne of the Henri Mondor Hospital. The study's product will be prepared with Base Tobramycin and excipients in accordance with TOBI's composition.
Study: NCT02638896
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib (0.4g/d) will be the background therapy.
Study: NCT04468984
Drug: Best Available Therapy (BAT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet/Capsule; Oral or Solution for Subcutaneous Injection
Study: NCT03697824
Drug: GSK3377794
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3377794 is genetically engineered NY-ESO-1 Specific (c259) T cells.
Study: NCT03697824
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be used as a lymphodepleting chemotherapy.
Study: NCT01780909
Drug: Paromomycin Sulfate Fasted State
Normalized name: Paromomycin Sulfate
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01780909
Drug: Paromomycin Sulfate Fed State
Normalized name: Paromomycin Sulfate
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01780909
Drug: Paromomycin Sulfate w/ loperamide HCl
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01044420
Drug: mFOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFIRI irinotecan 130-150mg/m2 iv d1 LV 200 mg/m2 iv 2h d1 5-FU 400 mg/m2 IV d1 5-FU 2.4-3 g/m2 CI 46-h repeat every 2 weeks
Study: NCT02871401
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with IPF currently tolerating pirfenidone treatment who have evidence of prior EBV or CMV infection will be randomized to valganciclovir or placebo for 12 weeks.
Study: NCT01193816
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02935699
Drug: Test Drug (JDP-205)
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine, 10mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
Study: NCT02156492
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT00374855
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03264794
Drug: Gefitinib tablets (Yi Ruisha），First medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib tablets (Yi Ruisha），First medication,250mg；
Study: NCT04080869
Drug: retinyl palmitate
Normalized name: Retinyl palmitate
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical retinyl palmitate loaded ethosomes
Study: NCT04080869
Drug: Tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topical tretinoin
Study: NCT00002783
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04977882
Drug: Postoperative antibiotico-prophylaxis
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftriaxone 2 gr and Metronidazole 1.5 gr per day for 2 days postoperatively
Study: NCT01935817
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01300546
Drug: Sumatriptan/Naproxen Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each tablet of Treximet for oral administration contains Sumatriptan 85mg / Naproxen Sodium 500mg. Study medication is to be administered within 1 hour of migraine onset on 14 or fewer days per month in the Treatment Period.
Study: NCT01300546
Drug: Naproxen Sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each tablet of Naproxen Sodium for oral administration is provided in 500mg tablet. Study medication is to be administered within 1 hour of migraine onset on 14 or fewer days per month in the Treatment Period.
Study: NCT03511599
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet matched to cycloserine tab
Study: NCT02708771
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 daily capsules of similar appearance and flavor without active ingredient
Study: NCT04146376
Drug: VWF replacement therapy with Wilate
Normalized name: factor VIII / von Willebrand factor Injection [Wilate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study design uses on-label Wilate for VWF replacement therapy for delivery and the postpartum period in VWD patients whose VWF levels are \<100% in the third trimester of pregnancy
Study: NCT02155361
Drug: Topical Citrullus colocynthis fruit oil (1%)
Normalized name: Citrullus colocynthis fruit extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02152254
Drug: Standard-of-Care Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care treatment regimen will be left to the discretion of the treating physician.
Study: NCT03106948
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will undergo endoluminal biopsy prior to angioplasty but will NOT undergo insertion of the ACT drug delivery catheter
Study: NCT03106948
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subject will undergo endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) will be injected following conventional balloon angioplasty
Study: NCT03106948
Drug: Cuprimine Oral Product
Normalized name: Cuprimine Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will undergo endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) in combination with D-penicillamine (25 µM) will be injected following conventional balloon angioplasty
Study: NCT02160587
Drug: 0.9% Physiological Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Physiological Saline will be compared to ZuraPrep with regard to skin sensitization and irritation.
Study: NCT00990990
Drug: PNU-100480
Normalized name: Trichophyton antigen 1000 PNU/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg BID for 14 days
Study: NCT00990990
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: to match 100 mg BID for 14 days
Study: NCT00990990
Drug: PNU-100480
Normalized name: Trichophyton antigen 1000 PNU/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg BID for 14 days
Study: NCT00990990
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: to match 300 mg BID for 14 days
Study: NCT00990990
Drug: PNU-100480
Normalized name: Trichophyton antigen 1000 PNU/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg BID for 14 days
Study: NCT00990990
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: to match 600 mg BID for 14 days
Study: NCT00990990
Drug: PNU-100480
Normalized name: Trichophyton antigen 1000 PNU/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg QD for 14 days
Study: NCT00990990
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: to match 1200 mg QD for 14 days
Study: NCT00990990
Drug: PNU-100480
Normalized name: Trichophyton antigen 1000 PNU/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg BID for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
Study: NCT00990990
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to match 600 mg BID for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
Study: NCT00990990
Drug: PNU-100480
Normalized name: Trichophyton antigen 1000 PNU/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNU-100480 dose up to total of 1200 mg daily for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
Study: NCT00990990
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to match dose up to total of 1200 mg daily for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
Study: NCT01019876
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01565707
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children aged 5 to 11 years and adolescents aged 12 to 17 years received matching placebo liquid suspension once a day orally via syringe for 12 weeks along with non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB. The initial dose started with the equivalent of 5 mg in adults, referred to as pediatric equivalent dose (PED) of 5 mg (PED5), based on body weight for three weeks and was titrated up or down in up to three titration steps of three weeks each to reach the optimal dose. Titration up or down could lead to weight-based doses equivalent to doses in adults of 2.5 mg, 5 mg, 7.5 mg or 10 mg once daily and were referred to as PED2.5, PED5, PED7.5 and PED10. The minimum dose was PED2.5, and the maximum dose was PED10. The decision to titrate up or down was made by the investigator using information from the 7 day patient diary.
Study: NCT03335956
Drug: CORT125281, 40mg, fasted
Approvals — FDA: no, EMA: no, PMDA: no
Description: CORT125281 is supplied as capsules for oral dosing
Study: NCT03335956
Drug: Placebo oral capsule, fasted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered
Study: NCT03335956
Drug: Placebo oral capsule, fed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered
Study: NCT03335956
Drug: CORT125281, 120mg, fasted
Approvals — FDA: no, EMA: no, PMDA: no
Description: CORT125281 is supplied as capsules for oral dosing
Study: NCT03335956
Drug: CORT125281, 360mg, fasted
Approvals — FDA: no, EMA: no, PMDA: no
Description: CORT125281 is supplied as capsules for oral dosing
Study: NCT03335956
Drug: CORT125281, 720mg, fasted
Approvals — FDA: no, EMA: no, PMDA: no
Description: CORT125281 is supplied as capsules for oral dosing
Study: NCT03335956
Drug: CORT125281, 360mg, fed
Approvals — FDA: no, EMA: no, PMDA: no
Description: CORT125281 is supplied as capsules for oral dosing
Study: NCT03335956
Drug: CORT125281, 360mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CORT125281 is supplied as capsules for oral dosing twice, 12 hours apart, fasted (morning) and after evening meal
Study: NCT03335956
Drug: CORT125281, 360mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CORT125281 is supplied as capsules for oral dosing once daily
Study: NCT03335956
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered twice, 12 hours apart, fasted (morning) and after evening meal
Study: NCT03335956
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered, twice daily
Study: NCT03335956
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered, once daily
Study: NCT03591094
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00868166
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules of Placebo once a day with the noon meal as add-on therapy to riluzole 50mg bid
Study: NCT00435604
Drug: Hylenex
Normalized name: Hylenex
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01586143
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00833638
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet orally daily
Study: NCT00364429
Drug: [123]I-CNS 1261
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study Drug
Study: NCT00793468
Drug: GSK598809
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK598809 once daily for 12 weeks
Study: NCT04047862
Drug: 5fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered in accordance with local guidelines , prescribing information/summary of product
Study: NCT04047862
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered in accordance with local guidelines , prescribing information/summary of product
Study: NCT00793468
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 12 weeks
Study: NCT02348073
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two capsules will be swallowed twice daily, 20 to 30 minutes prior to breakfast and dinner, during 12 weeks, between visit 1 and visit 2.
Study: NCT03969719
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01029223
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02130193
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive danirixin matching placebo
Study: NCT03762473
Drug: Study Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will convert from current tacrolimus dose to an Envarsus dose that is 80% of the total tacrolimus dose. They will take envarsus once daily in the morning and have 24 hour trough levels monitored at the standard of care interval for tacrolimus. Dosing will be titrated to achieve goal levels.
Study: NCT03762473
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post transplant patients (kidney transplant alone) performed between 10-2016 and time of enrollment with standard of care immunosuppression, no prior rejection, prior BK or opportunistic infection, whom had a negative BK screening at month 1 and concentration/dose of \< 1 at month 1, and BK data available and month 2,3, 6,9,12.
Study: NCT00636610
Drug: Modified FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following administration of bevacizumab, patients received oxaliplatin 85 mg/m\^2 IV administered over 90 minutes concurrently with folinic acid 400 mg/m\^2 (d,I-racemic form, or 200 mg/m\^2 I-isomer form) IV administered over 120 minutes, then fluorouracil 400 mg/m\^2 administered as an IV bolus, then 2400 mg/m\^2 administered as a continuous IV infusion over 46 hours.
Study: NCT00636610
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following administration of bevacizumab, patients received irinotecan 180 mg/m\^2 IV administered over 90 minutes concurrently with folinic acid 400 mg/m\^2 (d,I-racemic form, or 200 mg/m\^2 I-isomer form) administered IV over 120 minutes, then fluorouracil 400 mg/m\^2 administered as an IV bolus, then fluorouracil 2400 mg/m\^2 administered as a continuous IV infusion over 46 hours.
Study: NCT03759938
Drug: Direct oral anticoagulant (DOAC)
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any of the DOACs listed above may be used for treatment in either study arm. The DOAC will be supplied from normal hospital stock, using local hospital prescriptions.
Study: NCT00843661
Drug: pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg pravastatin/day
Study: NCT03348163
Drug: Current ART
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current ART is emtricitabine plus tenofovir disoproxil fumarate or tenofovir alafenamide plus 3rd agent.
Study: NCT03576664
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cross-over, randomized, placebo-controlled study.
Study: NCT02585778
Drug: Antihyperglycemic Drug
Normalized name: ANTIHYPOGLYCEMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (injectable or inhaled) alone or with other antihyperglycemic drugs as clinically indicated.